Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Apr 18, 2023; 11(4): 125-133
Published online Apr 18, 2023. doi: 10.13105/wjma.v11.i4.125
Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis
Manisha Thakur, Akhil Babu, Gopal Lal Khatik, Ashok Kumar Datusalia, Ramchander Khatri, Anoop Kumar
Manisha Thakur, Ashok Kumar Datusalia, Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli, Raebareli 226002, India
Akhil Babu, Gopal Lal Khatik, Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Raebareli, Raebareli 226002, India
Ramchander Khatri, Department of Pharmacognosy, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India
Anoop Kumar, Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India
Author contributions: Thakur M and Babu A contributed to searching and selection of studies, extraction of data; Khatik GL, Datusalia AK, and Khatri R contributed to cross verification of data; Khatik GL contributed to first draft of the manuscript; Datusalia AK and Khatri R contributed to revision; Kumar A contributed to design, analysis and final rthe evision of manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anoop Kumar, PhD, Assistant Professor, Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India. abitmesra@gmail.com
Received: October 31, 2022
Peer-review started: October 31, 2022
First decision: January 17, 2023
Revised: January 27, 2023
Accepted: March 29, 2023
Article in press: March 29, 2023
Published online: April 18, 2023
Processing time: 179 Days and 7.3 Hours
Core Tip

Core Tip: Emerging reports have indicated the use of baricitinib in hospitalized coronavirus disease 2019 (COVID-19) patients. However, the use of baricitinib in COVID-19 patients is unclear so far. Current study aimed to find out the exact association of baricitinib in the mortality of COVID-19 patients.